In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject
US-10907135-B2 · Feb 2, 2021 · US
Modified Brucella vaccine strain for the treatment of brucellosis
US11298416B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11298416-B2 |
| Application number | US-201816766629-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 26, 2018 |
| Priority date | Nov 24, 2017 |
| Publication date | Apr 12, 2022 |
| Grant date | Apr 12, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application provides a modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The Brucella strain has been modified through an inactivation of the wzm gene. Further, the present application provides a pharmaceutical composition which comprises the modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The present application also provides a kit which comprises the modified Brucella strain and a pharmaceutically acceptable carrier or diluent and its use for the treatment and/or prevention of brucellosis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for prevention of brucellosis, comprising administering to a subject a modified Brucella melitensis Rev1 strain, wherein the wzm gene has been inactivated, wherein the method is for prevention of brucellosis in cattle, goats, sheep, pigs, dogs, or combinations thereof, and the brucellosis is caused by an infectious agent selected from the group consisting of B. melitensis, B. abortus and B. ovis. 2. The method according to claim 1 , wherein the wzm gene has been partially deleted. 3. The method according to claim 2 , wherein at least 50% of SEQ ID NO: 1 has been deleted. 4. The method according to claim 1 , wherein the strain has been further modified to express a fluorescent protein. 5. The method according to claim 1 , wherein the strain has been lyophilized.
Assignees
Inventors
Classifications
- A61K39/098Primary
Brucella · CPC title
Antibacterial agents · CPC title
avirulent or attenuated · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11298416B2 cover?
- The present application provides a modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The Brucella strain has been modified through an inactivation of the wzm gene. Further, the present application provides a pharmaceutical composition which comprises the modified Brucella strain, its use as a medicament, and its us…
- Who is the assignee on this patent?
- Consejo Superior Investigacion, Univ Navarra Publica
- What technology area does this patent fall under?
- Primary CPC classification A61K39/098. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).